(XLV) Health Care Sector SPDR Fund - Ratings and Ratios
Pharmaceuticals, Biotech, Medical Devices, Provider Services
Description: XLV Health Care Sector SPDR Fund October 14, 2025
The Health Care Select Sector SPDR® Fund (XLV) seeks to replicate the performance of its underlying index by investing at least 95 % of assets in the constituent securities. The index is composed of companies across pharmaceuticals, health-care equipment & supplies, health-care providers & services, biotechnology, life-sciences tools & services, and health-care technology, and the ETF is classified as a non-diversified fund.
Key quantitative points to note: XLV’s expense ratio stands at 0.12 %, placing it among the lower-cost options in the health-care ETF space; as of the latest reporting period, the fund holds roughly $30 B in assets under management, with the top five holdings (e.g., UnitedHealth Group, Johnson & Johnson, Pfizer, Merck, and AbbVie) together accounting for about 45 % of total net assets. Sector-level drivers include an aging U.S. population, rising Medicare/Medicaid expenditures, and sustained R&D pipelines in biotech, all of which historically support a long-term growth bias for health-care equities.
For a deeper, data-driven look at XLV’s risk-adjusted performance and valuation metrics, the ValueRay platform provides a transparent dashboard that can help you evaluate whether the fund aligns with your investment objectives.
XLV ETF Overview
| Market Cap in USD | 36,829m |
| Category | Health |
| TER | 0.09% |
| IPO / Inception | 1998-12-16 |
XLV ETF Ratings
| Growth Rating | 16.8% |
| Fundamental | - |
| Dividend Rating | 58.9% |
| Return 12m vs S&P 500 | -16.9% |
| Analyst Rating | - |
XLV Dividends
| Dividend Yield 12m | 1.68% |
| Yield on Cost 5y | 2.60% |
| Annual Growth 5y | 7.97% |
| Payout Consistency | 96.2% |
| Payout Ratio | % |
XLV Growth Ratios
| Growth Correlation 3m | 86.8% |
| Growth Correlation 12m | -38.7% |
| Growth Correlation 5y | 84.5% |
| CAGR 5y | 4.84% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.28 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.86 |
| Sharpe Ratio 12m | 0.52 |
| Alpha | -15.90 |
| Beta | 0.680 |
| Volatility | 11.49% |
| Current Volume | 8621k |
| Average Volume 20d | 9031.8k |
| Stop Loss | 141 (-3.1%) |
| Signal | -0.34 |
What is the price of XLV shares?
Over the past week, the price has changed by +0.22%, over one month by +7.03%, over three months by +8.00% and over the past year by -0.51%.
Is Health Care Sector SPDR Fund a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XLV is around 136.98 USD . This means that XLV is currently overvalued and has a potential downside of -5.82%.
Is XLV a buy, sell or hold?
What are the forecasts/targets for the XLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 152.8 | 5% |
XLV Fundamental Data Overview October 25, 2025
Beta = 0.68
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 36.83b USD (36.83b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 36.83b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 36.83b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.52% (E(36.83b)/V(36.83b) * Re(8.52%) + (debt-free company))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XLV ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle